Project Grant R37CA300358
Award Date 8/18/25
Completion Date 7/31/30
Dollars Obligated $517K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This Project Grant award of $734,435.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance cancer treatment research for acute myeloid leukemia (AML). The primary recipient, Beckman Research Institute of the City of Hope, will conduct research to investigate how inhibiting the ADSS2 enzyme can sensitize drug-resistant AML to BH3 mimetic therapies. The research will use patient-derived xenograft models to understand the molecular mechanisms underlying...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
- This federal Project Grant award of $738,698 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel treatment approach for relapsed and refractory acute myelogenous leukemia (AML). The principal investigator and awardee, Beckman Research Institute of the City of Hope, will investigate combining targeted radioimmunotherapy using an anti-CD38 alpha-emitter with total marrow irradiation and a reduced-intensity conditioning regimen for AML...
- This $483,110 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to dissect the functional role of PAX5 mutations in B-cell acute lymphoblastic leukemia (B-ALL). The 5-year project, starting on September 1, 2025, will use orthogonal experimental models and multi-omics platforms to systematically investigate the mechanisms underlying differential clinical responses observed between two PAX5-driven B-ALL subtypes, PAX5alt and PAX5 p80R....
- This $3,480,276.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL) in order to identify genetic predictors of relapse and therapeutic vulnerabilities. The principal investigators at Seattle Children's Hospital, a leading pediatric research and healthcare...
- The National Cancer Institute (NCI) awarded a $721,723 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Beckman Research Institute of the City of Hope. The grant supports research to understand the biological mechanisms driving the transition from chronic lymphocytic leukemia (CLL) to the more aggressive Richter's transformation (RT), a devastating complication with poor prognosis. Key objectives include determining how the MGA/MYC/NME1 regulatory axis impacts tumor...
- This Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), provides $484,405 to Thomas Jefferson University to investigate how mutations in the NSD2 gene drive the transformation and progression of acute lymphoblastic leukemia (ALL), a common childhood cancer. The key research objectives are to: Determine the mechanisms by which NSD2 mutations promote leukemia transformation in hematopoietic stem cells. Evaluate the...
- The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $941,798 in funding to the Beckman Research Institute of the City of Hope to conduct research on the mechanisms of RNA modification-mediated codon-biased translation in acute myeloid leukemia (AML). The project aims to elucidate how the ALKBH1 enzyme regulates codon-biased translation of oncogenic targets to promote AML development and therapeutic resistance, with the goal of...
- The Sloan-Kettering Institute for Cancer Research received a $1,034,176 Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to conduct research aimed at understanding the genetic and biological mechanisms underlying the development and progression of various types of leukemia. The 7-year grant, awarded on August 18, 2025, will support the principal investigator's laboratory in pursuing several key objectives: Elucidating the genetic alterations and...